Endo-Epicardial Ventricular Tachycardia Ablation With Pulsed-Field Energy in an Extravascular ICD Recipient Authors: Pranav Bhagirath, Raimondo Pittorru, Mariona Regany, Nicola Pierucci, José M. Tolosana, Jorge Alcocer, Andreu Porta-Sanchez, Ivo Roca-Luque Published: 2026 ABSTRACT BackgroundExtravascular implantable cardioverter-defibrillator (EV-ICD) recipients may require epicardial ventricular tachycardia (VT) ablation, raising device and access considerations.First-in-Human/Early Reports SummaryA 62-year-old man with ischemic cardiomyopathy (left ventricular ejection fraction: 38%) and electrical storm despite antiarrhythmics and prior endocardial ablation underwent hybrid endo-epicardial VT ablation guided by right ventricular apex S1-S2-S3 mapping. A basal-mid inferolateral epicardial deceleration zone with local abnormal ventricular activity and a diastolic pathway were targeted. Pulsed-field (PF) applications with limited adjunct radiofrequency (RF) abolished the epicardial deceleration zone and the clinical VT; a rapid nonclinical VT remained inducible. Concomitant substernal lead repositioning was performed for noise oversensing. No complications occurred; defibrillation testing was effective, and 30-day remote monitoring showed no arrhythmic events.DiscussionA pragmatic workflow integrated computed tomography–guided epicardial planning, functional substrate mapping, PF ± RF delivery, and EV-ICD management.NoveltyThis is to our knowledge the first reported combination of PF-based endo-epicardial VT ablation with concomitant substernal lead repositioning in an EV-ICD recipient.Take-Home MessageHybrid PF-based VT ablation can be integrated with EV-ICD management. The extravascular implantable cardioverter-defibrillator (EV-ICD) provides defibrillation and antitachycardia pacing without transvenous leads, using a substernal lead configuration. As EV-ICD implantation expands, operators will increasingly encounter recipients requiring ventricular tachycardia (VT) ablation, including epicardial strategies. Key procedural challenges include safe epicardial access and lesion delivery in the context of a substernal lead, as well as structured documentation of device integrity after ablation and any lead manipulation. Although epicardial VT ablation in EV-ICD recipients has been described, published experience remains limited and has largely focused on radiofrequency (RF) strategies. This case highlights a hybrid endo-epicardial workflow incorporating pulsed-field (PF) energy delivery and concomitant substernal lead management, with event-free 30-day follow-up.Take-Home Messages•Hybrid endo-epicardial ventricular tachycardia ablation incorporating pulsed-field applications is feasible in EV-ICD recipients using pulsed-field ablation in epicardium, overcoming the risk of phrenic nerve damage and the limitations of radiofrequency in the presence of epicardial fat.•In EV-ICD patients with clinically significant noise oversensing attributed to substernal lead movement and sensing variability, concomitant lead repositioning during the same admission can be integrated into the ablation workflow to mitigate inappropriate therapy risk. Take-Home Messages •Hybrid endo-epicardial ventricular tachycardia ablation incorporating pulsed-field applications is feasible in EV-ICD recipients using pulsed-field ablation in epicardium, overcoming the risk of phrenic nerve damage and the limitations of radiofrequency in the presence of epicardial fat.•In EV-ICD patients with clinically significant noise oversensing attributed to substernal lead movement and sensing variability, concomitant lead repositioning during the same admission can be integrated into the ablation workflow to mitigate inappropriate therapy risk. •Hybrid endo-epicardial ventricular tachycardia ablation incorporating pulsed-field applications is feasible in EV-ICD recipients using pulsed-field ablation in epicardium, overcoming the risk of phrenic nerve damage and the limitations of radiofrequency in the presence of epicardial fat. Hybrid endo-epicardial ventricular tachycardia ablation incorporating pulsed-field applications is feasible in EV-ICD recipients using pulsed-field ablation in epicardium, overcoming the risk of phrenic nerve damage and the limitations of radiofrequency in the presence of epicardial fat. •In EV-ICD patients with clinically significant noise oversensing attributed to substernal lead movement and sensing variability, concomitant lead repositioning during the same admission can be integrated into the ablation workflow to mitigate inappropriate therapy risk. In EV-ICD patients with clinically significant noise oversensing attributed to substernal lead movement and sensing variability, concomitant lead repositioning during the same admission can be integrated into the ablation workflow to mitigate inappropriate therapy risk. Case Presentation Patient history A 62-year-old man with hypertension, dyslipidemia, class III obesity (body mass index: 44 kg/m2), and obstructive sleep apnea on continuous positive airway pressure had chronic ischemic cardiomyopathy since 2011 (3-vessel coronary artery disease with chronic total occlusions of the right coronary artery and left circumflex artery, and prior percutaneous coronary intervention to the first obtuse marginal in 2011). Repeat angiography in 2015 confirmed complex multivessel disease managed medically. Cardiac magnetic resonance imaging showed prior infarctions, and an echocardiogram in December 2025 demonstrated a left ventricular ejection fraction of 38% with inferolateral basal aneurysmal features and akinesia in basal anterolateral/inferolateral segments, without significant valvular disease or pericardial effusion. The patient initially received a transvenous ICD (Biotronik) in 2011 after syncope and inducible VT during electrophysiology study. He experienced appropriate ICD shocks in 2015, and later inappropriate shocks due to lead failure requiring surgical revision in 2019. Given additional VT episodes in November 2024, he underwent endocardial VT ablation targeting the clinical VT, with persistence of inducible epicardial VT. He developed further lead fracture with noise oversensing in 2025 and underwent implantation of an Aurora EV-ICD (Medtronic), with 2 abandoned endocardial defibrillation leads remaining in situ. Presentation and arrhythmia characterization The patient was admitted for recurrent symptomatic sustained monomorphic VT (cycle length: 440-460 ms) and ICD therapies. Device interrogation documented true VT episodes (including a sustained episode terminated with multiple antitachycardia pacing sequences and a shock) as well as multiple detections driven by noise oversensing (misclassified as ventricular fibrillation/nonsustained VT), consistent with lead-related sensing instability. He was treated with antiarrhythmic escalation (amiodarone and mexiletine; later mexiletine 200 mg every 8 hours, amiodarone 200 mg daily, propranolol 20 mg every 8 hours) and underwent repeat coronary angiography during admission, confirming patent prior stents and no new culprit lesions. Given electrical storm without an ischemic trigger and known residual epicardial substrate from prior procedures, a multidisciplinary decision was made to proceed with hybrid epicardial VT ablation. Preprocedural EV-ICD findings Before ablation, the EV-ICD demonstrated noise oversensing attributed to substernal lead movement with variability in R-wave amplitude, raising concern for inappropriate therapy (Figure 1). Sensing was programmed on Ring 2-high-voltage anode, sensitivity 0.3 mV, with oversensing prevention settings per institutional protocol. Preprocedural device parameters included R-wave amplitude 0.9 to 1.25 mV (stable across interrogations), impedance ring-coil 418 Ω, ring1-ring2 608 Ω, high-voltage impedance 153 Ω with charge time 9.2 seconds. Given the clinical importance of stabilizing sensing and preventing inappropriate therapy, concomitant substernal lead repositioning was planned during the same admission. Procedure Written informed consent was obtained. At the time of this procedure, the dual-energy PF/RF catheter system used for PF applications was not approved for VT ablation in the U.S./EU. It was used in our center under local institutional governance and standard clinical oversight. The consent process explicitly addressed the off-label use of PF energy for VT, including potential risks and uncertainties, and written patient consent for publication was obtained. The procedure was performed under general anesthesia with invasive arterial blood pressure monitoring. Femoral venous access was obtained (3 venous sheaths), and diagnostic catheters were positioned for recording and stimulation. Epicardial access was obtained via a surgical subxiphoid window performed by a cardiac surgeon. A guidewire was advanced into the pericardial space and a steerable epicardial sheath (Agilis Epi) was introduced. Three-dimensional reconstruction with EnSite X (Abbott) was performed with computed tomography (CT) fusion (magnetic resonance imaging was not feasible because of abandoned leads/EV-ICD). Epicardial substrate mapping using an HD Grid catheter (Abbott) and an S1-S2-S3 protocol was focused to the inferolateral scar region identified by CT using wall thickness/hypoenhancement (Figure 2). Mapping demonstrated a localized basal-mid inferolateral region of slow conduction (deceleration zone) and local abnormal ventricular activity during sinus rhythm (Figure 3, top).Figure 2Structural Substrate and EV-ICD Anatomy(Top Left) Late gadolinium enhancement CMR short-axis images demonstrating anterior-anterolateral enhancement (arrows) consistent with prior infarction and supporting an epicardial substrate component. (Top Right) CT images with wall-thinning and hypoenhancement in the lateral region at the basal to mid ventricular level (arrows). (Bottom Row) CT-based 3-dimensional reconstruction illustrating a large layer of epicardial fat and the relationship between the inferolateral scar region and the substernal EV-ICD lead course (Aurora EV-ICD system), used for procedural planning and anatomical context during the hybrid endo-epicardial procedure. CMR = cardiac magnetic resonance; CT = computed tomography; EV-ICD = extravascular implantable cardioverter-defibrillator.Figure 3Epicardial and Endocardial S3 Activation Mapping(Top) Epicardial and (Bottom) endocardial S3 activation maps acquired during an RV apex S1-S2-S3 pacing protocol, demonstrating a localized basal-mid inferolateral region of delayed activation/slow conduction (white dotted circle) corresponding to the targeted deceleration zone. Representative electrograms recorded within the region show late potentials with decremental properties indicative of functional substrate. RV = right ventricular. Structural Substrate and EV-ICD Anatomy (Top Left) Late gadolinium enhancement CMR short-axis images demonstrating anterior-anterolateral enhancement (arrows) consistent with prior infarction and supporting an epicardial substrate component. (Top Right) CT images with wall-thinning and hypoenhancement in the lateral region at the basal to mid ventricular level (arrows). (Bottom Row) CT-based 3-dimensional reconstruction illustrating a large layer of epicardial fat and the relationship between the inferolateral scar region and the substernal EV-ICD lead course (Aurora EV-ICD system), used for procedural planning and anatomical context during the hybrid endo-epicardial procedure. CMR = cardiac magnetic resonance; CT = computed tomography; EV-ICD = extravascular implantable cardioverter-defibrillator. Epicardial and Endocardial S3 Activation Mapping (Top) Epicardial and (Bottom) endocardial S3 activation maps acquired during an RV apex S1-S2-S3 pacing protocol, demonstrating a localized basal-mid inferolateral region of delayed activation/slow conduction (white dotted circle) corresponding to the targeted deceleration zone. Representative electrograms recorded within the region show late potentials with decremental properties indicative of functional substrate. RV = right ventricular. During catheter manipulation, a monomorphic VT (right bundle branch block, inferior axis, positive concordance in precordial leads) was mechanically induced and was hemodynamically poorly tolerated. Given instability, limited activation mapping demonstrated a diastolic pathway with diastolic potentials recorded in the inferolateral basal-mid epicardial region (Figure 4). The VT degenerated into ventricular fibrillation requiring cardioversion/defibrillation. Coronary safety was assessed using preprocedural coronary CT segmentation with integration/fusion into the electroanatomic map to confirm distance from epicardial coronary trajectories and avoid energy delivery directly overlying coronary courses, with continuous electrocardiographic monitoring during PF applications. Intravenous nitroglycerin was administered during the procedure. Phrenic nerve proximity was noted on integrated imaging, favoring a strategy prioritizing minimized collateral injury risk. Furthermore, preprocedural CT demonstrated a substantial epicardial fat layer overlying the target region, which can attenuate effective epicardial RF lesion delivery1 and influenced our choice to prioritize PF energy for epicardial substrate modification.2Figure 4VT Targeting and Termination With Pulsed-Field DeliveryComposite procedural display showing the targeted inferolateral substrate region and ablation catheter position at the site labeled “STOP VT.” The accompanying intracardiac and surface ECG recordings illustrate delivery of pulsed-field energy (“PF on”) at the target site during unstable VT, followed by VT termination to sinus rhythm. Insets provide anatomical context and localization of the lesion set relative to the mapped slow-conduction region. ECG = electrocardiographic; PF = pulsed field; VT = ventricular tachycardia. VT Targeting and Termination With Pulsed-Field Delivery Composite procedural display showing the targeted inferolateral substrate region and ablation catheter position at the site labeled “STOP VT.” The accompanying intracardiac and surface ECG recordings illustrate delivery of pulsed-field energy (“PF on”) at the target site during unstable VT, followed by VT termination to sinus rhythm. Insets provide anatomical context and localization of the lesion set relative to the mapped slow-conduction region. ECG = electrocardiographic; PF = pulsed field; VT = ventricular tachycardia. A dual-energy focal catheter (TactiFlex Duo Dual Energy, 3.5-mm irrigated; Abbott) was advanced epicardially. Pace mapping at the site of diastolic potentials demonstrated high concordance with the VT exit (>90%) with long S-QRS. VT was reinduced (cycle length: ±450 ms), with poor tolerance, and PF applications were delivered at the diastolic pathway and across the previously identified epicardial slow-conduction substrate. A total of 18 PF applications (144 pulses) were delivered (with impedance drop observed during delivery), resulting in VT termination to sinus rhythm within seconds (Figure 4). Two abandoned transvenous defibrillation leads were present. Their course and coil position were reviewed on preprocedural CT/fluoroscopy, and PF applications were delivered away from the abandoned coils. No arcing, unexpected capture, or abrupt impedance anomalies were observed during PF delivery. Remapping demonstrated abolition of the epicardial deceleration zone, with residual slow-conduction signals and inducible VT requiring cardioversion. Given evidence of endocardial/transmural involvement, endocardial ablation was performed via transseptal access with full heparinization. Endocardial S1-S2-S3 mapping with the HD Grid identified a basal inferolateral slow-conduction region corresponding to CT-defined channels and opposite the epicardial substrate (Figure 3, bottom). This region was treated using additional PF applications with previous RF (30 W) lesions to increase lesion depth. Repeat epicardial and endocardial remapping showed no residual slow-conduction zones (Figure 5). Final programmed stimulation did not reinduce the previously targeted clinical VT.Figure 5Preablation and Postablation S3 Activation RemappingEpicardial and endocardial S3 activation maps acquired during an RV apex S1-S2-S3 pacing protocol (Left) before and (Right) after completion of the final lesion set. Postablation remapping demonstrates abolition of the previously identified inferolateral slow-conduction region/delayed activation zone, consistent with acute substrate modification. Color scaling and display settings are kept consistent within chamber for pre- versus postablation comparison. RV = right ventricular. Preablation and Postablation S3 Activation Remapping Epicardial and endocardial S3 activation maps acquired during an RV apex S1-S2-S3 pacing protocol (Left) before and (Right) after completion of the final lesion set. Postablation remapping demonstrates abolition of the previously identified inferolateral slow-conduction region/delayed activation zone, consistent with acute substrate modification. Color scaling and display settings are kept consistent within chamber for pre- versus postablation comparison. RV = right ventricular. During the same procedure, the substernal EV-ICD lead was repositioned via the subxiphoid approach by the surgical team to achieve stable lead position and acceptable device parameters, in the context of preprocedural noise oversensing consistent with lead movement and R-wave variability. The lead was secured and therapies were reactivated. The procedure ended without complications. An epicardial drain was placed and maintained per protocol. Bedside echocardiography showed no pericardial effusion. Outcomes and Follow-Up Postablation interrogation documented bipolar sensing of approximately 1.0 to 2.4 mV (within the normal range). A defibrillation/induction test was effective at 30 J without incident. Remote transmission at ±30 days demonstrated no new arrhythmic events. Programming at follow-up was documented as VT 176 beats/mins, TV2 200 beats/mins, FV >200 beats/min. Battery estimate was 9.5 years (2.99 V). Sensed R-wave amplitude was 0.6 mV. Impedance values included ring1-ring2 304 Ω, ring1-bobina2 171 Ω, and high-voltage impedance 55 Ω. Notably, the 30-day R-wave amplitude was lower than the preprocedural range (0.9-1.25 mV) despite lead repositioning, demonstrating that concomitant repositioning does not necessarily result in durable increases in sensed amplitude. Given the short follow-up and known variability in EV-ICD sensing and impedance measurements, these findings should be interpreted as short-term observations; longer follow-up with serial interrogation is required to assess durability of device parameters and procedural efficacy. Novelty To the best of our knowledge, this is the first reported experience of a hybrid endo-epicardial VT ablation using PF applications delivered with a dual-energy PF/RF focal catheter in a patient with an EV-ICD, combined with surgical subxiphoid epicardial access and concomitant substernal lead repositioning performed for clinically significant noise oversensing attributed to lead movement and R-wave variability, with preserved defibrillation function and event-free 30-day follow-up. Future Directions This case supports the feasibility of a reproducible hybrid workflow integrating: 1) imaging-informed epicardial access via a subxiphoid window; 2) S1-S2-S3 substrate mapping to localize discrete slow-conduction channels and local abnormal ventricular activity; 3) PF energy delivery in ventricular substrate with adjunct RF for residual conduction in transmural scar; and 4) structured EV-ICD integrity assessment with short-term outcome monitoring. Epicardial fat is an actionable finding on preprocedural CT that may influence epicardial lesion delivery and energy selection; future studies should prospectively capture CT-derived epicardial fat thickness at target sites and correlate it with acute substrate endpoints (eg, deceleration zone abolition on S3 remapping), procedural efficiency, and recurrence. Because field behavior in adipose tissue is complex and attenuation is not negligible, this observation should be considered hypothesis-generating rather than demonstrative.2 Future work should include prospective registries or early feasibility cohorts capturing energy modality (PF vs RF), lesion sets (epicardial vs endocardial), coronary/phrenic safety strategy, defibrillation testing practice, and longitudinal sensing/impedance trends in EV-ICD recipients undergoing ablation. Standardized reporting of lead position management (including indications such as noise oversensing related to movement) will be important to define best practices. Conclusions This case illustrates a pragmatic hybrid workflow in an EV-ICD recipient: CT-informed subxiphoid epicardial access, S1-S2-S3 mapping to localize a discrete inferolateral slow-conduction channel, and PF applications (with limited adjunct RF) to achieve substrate elimination. Concomitant substernal lead repositioning addressed clinically relevant noise oversensing and enabled immediate postprocedure defibrillation testing. Short-term follow-up was reassuring, while durability of arrhythmia control and device parameters requires longer surveillance.Figure 1EV-ICD Electrograms Demonstrating Noise Oversensing Before Lead RepositioningImplantable cardioverter-defibrillator transmission showing intermittent high-frequency noise on the sensing channel with variable signal amplitude during sinus rhythm, consistent with noise oversensing. EV-ICD = extravascular implantable cardioverter-defibrillator. EV-ICD Electrograms Demonstrating Noise Oversensing Before Lead Repositioning Implantable cardioverter-defibrillator transmission showing intermittent high-frequency noise on the sensing channel with variable signal amplitude during sinus rhythm, consistent with noise oversensing. EV-ICD = extravascular implantable cardioverter-defibrillator. Funding Support and Author Disclosures Drs Tolosana, Porta-Sanchez, and Roca-Luque have been consultants and lecturers for Biosense Webster, Medtronic, Boston Scientific, Atricure Inc, and Abbott Medical; and they are shareholders of Corify Care SL. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.Visual SummaryClinical Course Leading to Hybrid VT Ablation and EV-ICD RepositioningTimeKey Events2011PCI OM1; transvenous ICD placed after inducible VT/VF.2015Appropriate ICD shocks.2019Lead failure → surgical revision.2024Endocardial VT ablation for clinical VT; inducible epicardial VT remained.2025Aurora EV-ICD placed; 2 abandoned transvenous defibrillation leads present.2026Electrical storm; coronary ischemia excluded; antiarrhythmic escalation; noise oversensing noted.Surgical subxiphoid epicardial access; S1-S2-S3 mapping; PF ± RF ablation → epicardial DZ abolished and clinical VT noninducible; concomitant substernal lead repositioning; DFT test successful.Remote monitoring: no new arrhythmic events.DFT = defibrillation threshold; DZ = deceleration zone; EV-ICD = extravascular implantable cardioverter-defibrillator; ICD = implantable cardioverter-defibrillator; OM1 = first obtuse marginal; PCI = percutaneous coronary intervention; PF = pulsed field; RF = radiofrequency; VF = ventricular fibrillation; VT = ventricular tachycardia. Visual SummaryClinical Course Leading to Hybrid VT Ablation and EV-ICD RepositioningTimeKey Events2011PCI OM1; transvenous ICD placed after inducible VT/VF.2015Appropriate ICD shocks.2019Lead failure → surgical revision.2024Endocardial VT ablation for clinical VT; inducible epicardial VT remained.2025Aurora EV-ICD placed; 2 abandoned transvenous defibrillation leads present.2026Electrical storm; coronary ischemia excluded; antiarrhythmic escalation; noise oversensing noted.Surgical subxiphoid epicardial access; S1-S2-S3 mapping; PF ± RF ablation → epicardial DZ abolished and clinical VT noninducible; concomitant substernal lead repositioning; DFT test successful.Remote monitoring: no new arrhythmic events.DFT = defibrillation threshold; DZ = deceleration zone; EV-ICD = extravascular implantable cardioverter-defibrillator; ICD = implantable cardioverter-defibrillator; OM1 = first obtuse marginal; PCI = percutaneous coronary intervention; PF = pulsed field; RF = radiofrequency; VF = ventricular fibrillation; VT = ventricular tachycardia. Clinical Course Leading to Hybrid VT Ablation and EV-ICD Repositioning DFT = defibrillation threshold; DZ = deceleration zone; EV-ICD = extravascular implantable cardioverter-defibrillator; ICD = implantable cardioverter-defibrillator; OM1 = first obtuse marginal; PCI = percutaneous coronary intervention; PF = pulsed field; RF = radiofrequency; VF = ventricular fibrillation; VT = ventricular tachycardia.